

Food and Drug Administration Rockville MD 20857

FILE COPY

April 10, 2013

Peter R. Mathers Jennifer A. Davidson Kleinfeld, Kaplan and Becker, LLP 1140 Nineteenth Street, N.W. Washington, D.C. 20036-6606

Dear Mr. Mathers:

Your petition to the Food and Drug Administration on behalf of Rhodes Technologies, requesting FDA to take actions described in the petition with respect to 14-hydroxycodeinone impurity in oxycodone HCI API approved by FDA for use in drug products, was received by this office on 04/10/2013. It was assigned docket number FDA-2013-P-0425/CP1, and it was filed on 04/10/2013. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Gloria Ortega

Administrative Proceedings Officer Division of Dockets Management

FDA/Office of the Executive Secretariat (OES)